Cargando…
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: a pilot randomised controlled trial (PD COMM pilot)
BACKGROUND: Speech-related problems are common in Parkinson’s disease (PD), but there is little evidence for the effectiveness of standard speech and language therapy (SLT) or Lee Silverman Voice Treatment (LSVT LOUD®). METHODS: The PD COMM pilot was a three-arm, assessor-blinded, randomised control...
Autores principales: | Sackley, Catherine M., Smith, Christina H., Rick, Caroline E., Brady, Marian C., Ives, Natalie, Patel, Smitaa, Woolley, Rebecca, Dowling, Francis, Patel, Ramilla, Roberts, Helen, Jowett, Sue, Wheatley, Keith, Kelly, Debbie, Sands, Gina, Clarke, Carl E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763537/ https://www.ncbi.nlm.nih.gov/pubmed/29344405 http://dx.doi.org/10.1186/s40814-017-0222-z |
Ejemplares similares
-
Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM pilot): study protocol for a randomized controlled trial
por: Sackley, Catherine M, et al.
Publicado: (2014) -
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial
por: Scobie, Sarah, et al.
Publicado: (2021) -
A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial
por: Sackley, C. M., et al.
Publicado: (2020) -
Feasibility and Acceptability of Lee Silverman Voice Treatment in Progressive Ataxias
por: Lowit, Anja, et al.
Publicado: (2020) -
Lee Silverman voice treatment (LSVT) mitigates voice difficulties in mild Parkinson’s disease
por: Saffarian, Arezoo, et al.
Publicado: (2019)